TEM•benzinga•
Tempus AI Collaborates With Verastem Oncology To Develop Companion Diagnostic Test Using FDA-Approved xT CDx Assay For KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2025 by benzinga